Rolling heads at Roche
Roche way way way overpaid for Genentech. Avastin just failed colon cancer, got anti-edema for GBM. The latter sure looks great on paper but scientifically it's not much of treatment for GBM.
Iressa revival is going to take away a very lucrative niche market for lung cancer.
IF Roche isn't moving their butts this week -end and if they don't fork out pocket change for TLN (cause purchase price is pocket change for em) they will look like fools in Q3 when preliminary results are out for 4601.
They have this option to consider. Either they buy TLN or they face a very threatning AstraZeneca in 2 years.
Pocket change for protection or willful blindment in face of a new unexpected imminent danger.
Roche starting PIII trial for Tarceva is indicative of how annoyed they are by Iressa revival.
Don't think they'll just do that to counter AstraZeneca.
Don't think they'll just watch this small unknown company disappear and eaten up.
How much money did they wasted on Genentech? I know that if I was CEO of Roche, I would be have second guesses on myself and I would fork out an offer to TLN as an insurance against myself.
Happy week-end.
I think the facts are obvious. I am spelling it out but they are obvious.